Vimarsana
Biggest News Aggregation in the World

Disease Modification News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Disease Modification. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Disease Modification Today - Breaking & Trending Today

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson's Disease with its NLRP3 Inhibitor, Dapansutrile - Vimarsana News

Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson's Disease with its NLRP3 Inhibitor, Dapansutrile

Published: February 20, 2024

Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson's granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow...

Source: lelezard.com
Related Topics:
United KingdomCity OfDamaris SkourasQueen SquareCaroline Williams GrayCarolineh Williams GrayProduct ServiceJohn Black Charitable FoundationDepartment Of Clinical NeurosciencesOxford Clinical SchoolUniversity Of CambridgeVan Andel InstituteInternational Linked Clinical TrialsCambridge UniversityJohn Van Geest Centre For BrainOlatec Therapeutics IncCambridge Parkinson Disease Research ClinicEarly ParkinsonCure ParkinsonDisease ModificationRandomised Double Blind Placebo Controlled PhaseGeest CentreBrain RepairClinical NeurosciencesCambridge Parkinson
Neuroprotective Agents Market is set to Reach US$ 143.78 - Vimarsana News

Neuroprotective Agents Market is set to Reach US$ 143.78

Published: February 19, 2024

Pune, Feb. 19, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Neuroprotective Agents Market is...

Source: globenewswire.com
Related Topics:
United StatesAsia PacificPremium ResearchA Sample Copy Of The ResearchCustomer Base AssessmentStrategic DevelopmentYear For EstimationEphmra European Pharmaceutical Marketing Research AssociationRoute Of AdministrationGrowth Plus ReportsAgents MarketisNeuroprotective Agents MarketSample CopyResearch ReportSize ValueDistribution ChannelLatin AmericaMiddle EastMarket DriversNeurological DisordersDrug DiscoveryDisease ModificationPersonalized MedicineMarket TrendsCompetitive Positioning
Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES - Vimarsana News

Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES

Published: December 2, 2021

Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome...

Source: globenewswire.com
Related Topics:
United StatesPorter NovelliTrish MccallTevard BiosciencesBradleys GalerBrian RitchieUs Securities Exchange CommissionLifesci AdvisorsAmerican Epilepsy SocietyEuropean CommissionDrug AdministrationEuropean Early Access ProgramEuropean Medicines AgencyAnnual MeetingBetter Outcomes Through DiversityExecutive Vice PresidentChief Medical OfficerZogenix NewsroomTreatment Improves Everyday Executive FunctioningPreschool Children With Dravet SyndromeAnalysis FromSignificantly Reduces Day To Seizure BurdenIncreasing Seizure Free DaysTime To Event AnalysisEchocardiographic Assessment